Go Pro
→ Trump’s “BIG MISTAKE” stock is still dirt cheap (From Monument Traders Alliance) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.32
+0.7%		$4.15
$2.93
▼
$7.55
$542.21M1.493.09 million shs5.45 million shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$14.50
-0.2%		$14.13
$8.12
▼
$16.91
$545.49M0.74318,048 shs530,466 shs
Evolus, Inc. stock logo
EOLS
Evolus
$8.18
+5.3%		$6.69
$3.86
▼
$8.43
$540.29M1.351.04 million shs708,665 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.07
-2.7%		$1.23
$1.00
▼
$3.06
$133.21M0.981.90 million shs1.46 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+0.94%0.00%+4.13%+4.89%+4.38%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+2.40%+0.28%+2.11%+13.87%+96.88%
Evolus, Inc. stock logo
EOLS
Evolus
-4.66%+2.64%+35.60%+20.93%+15.45%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%-12.70%-7.17%-23.08%-35.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.32
+0.7%		$4.15
$2.93
▼
$7.55
$542.21M1.493.09 million shs5.45 million shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$14.50
-0.2%		$14.13
$8.12
▼
$16.91
$545.49M0.74318,048 shs530,466 shs
Evolus, Inc. stock logo
EOLS
Evolus
$8.18
+5.3%		$6.69
$3.86
▼
$8.43
$540.29M1.351.04 million shs708,665 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.07
-2.7%		$1.23
$1.00
▼
$3.06
$133.21M0.981.90 million shs1.46 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+0.94%0.00%+4.13%+4.89%+4.38%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+2.40%+0.28%+2.11%+13.87%+96.88%
Evolus, Inc. stock logo
EOLS
Evolus
-4.66%+2.64%+35.60%+20.93%+15.45%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%-12.70%-7.17%-23.08%-35.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$8.5096.99% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.40
Hold$20.2539.66% Upside
Evolus, Inc. stock logo
EOLS
Evolus
2.50
Moderate Buy$14.5077.39% Upside
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.67
Moderate Buy$7.25574.42% Upside

Current Analyst Ratings Breakdown

Latest MIST, EOLS, CTNM, and AQST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$22.00 ➝ $23.00
7/17/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/14/2026
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
6/17/2026
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
6/15/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/29/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$54.09M10.01N/AN/A($0.28) per share-15.41
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M10.91N/AN/A$6.99 per share2.07
Evolus, Inc. stock logo
EOLS
Evolus
$297.18M1.82N/AN/A($0.36) per share-22.71
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$2.34M57.12N/AN/A$0.39 per share2.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$83.78M-$0.65N/AN/AN/A-144.63%N/A-52.40%11/4/2026 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$59.98M-$1.73N/AN/AN/AN/A-24.73%-23.51%10/29/2026 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$51.64M-$0.52N/A102.18N/A-10.85%N/A-13.00%11/4/2026 (Estimated)
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$63.06M-$0.69N/AN/AN/AN/A-288.33%-58.27%N/A

Latest MIST, EOLS, CTNM, and AQST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.1950-$0.21-$0.0150-$0.21$0.82 million$0.56 million
8/11/2026Q2 2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.1050-$0.18-$0.0750-$0.18$11.42 million$13.82 million
7/30/2026Q2 2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.4488-$0.40+$0.0488-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
7.19
6.74
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
37.17
37.17
Evolus, Inc. stock logo
EOLS
Evolus
N/A
1.70
1.28
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3.25
8.13
7.92

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
6.81%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
7.90%
Evolus, Inc. stock logo
EOLS
Evolus
5.00%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
5.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
160125.51 million116.97 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3137.62 million34.65 millionN/A
Evolus, Inc. stock logo
EOLS
Evolus
17066.05 million62.75 millionOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
30124.50 million118.24 millionOptionable

Recent News About These Companies

Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
August 18 at 8:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4937577-milestone-pharmaceuticals-stock-reiterating-sell-as-the-losses-compound
HC Wainwright Has Bearish Estimate for MIST Q3 Earnings
August 16 at 1:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963148
HC Wainwright Brokers Decrease Earnings Estimates for MIST
August 15 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961887
What is HC Wainwright's Forecast for MIST Q3 Earnings?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-mist-q3-earnings-2026-08-14/
Milestone expects cash runway into second half of 2027 as CARDAMYST commercial coverage reaches 50%
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4631872-milestone-expects-cash-runway-into-second-half-of-2027-as-cardamyst-commercial-coverage
What is HC Wainwright's Estimate for MIST FY2028 Earnings?
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-mist-fy2028-earnings-2026-08-13/
Milestone Pharmaceuticals shares tumble after Q2 earnings miss
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/milestone-pharmaceuticals-shares-tumble-q2-120406464.html
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935389-milestone-pharmaceuticals-inc-mist-q2-2026-earnings-call-transcript
Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-nasdaqmist-releases-earnings-results-misses-expectations-by-001-eps-2026-08-12/
Milestone Pharmaceuticals Q2 Earnings Call Highlights
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-q2-earnings-call-highlights-2026-08-12/
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973298/milestone-pharmaceuticals-mist-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2973298
Milestone Pharmaceuticals Reports Q2 2026 Results, CARDAMYST Coverage Expands to Over 50% of Commercially Insured Lives and Phase 3 AFib-RVR Trial Opens
August 12, 2026  |  quiverquant.comQ
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343531/0/en/milestone-pharmaceuticals-announces-second-quarter-2026-financial-results-and-provides-corporate-update.html
Milestone Pharmaceuticals (MIST) to Announce Quarterly Earnings on Wednesday
August 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30953546
Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) PT at $7.25
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30946298
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Wednesday
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-mist-expected-to-announce-earnings-on-wednesday-2026-08-05/
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338778/0/en/milestone-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-august-12-2026.html
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-inc-nasdaqmist-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-08-02/
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
July 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2963002/after-plunging-20-2-in-4-weeks-here-s-why-the-trend-might-reverse-for-milestone-pharmaceuticals-mist?cid=cs-stocknewsapi-ft-tale_of_the_tape|rsi-2963002
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/03/3321626/0/en/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
June 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913890-milestone-pharmaceuticals-inc-mist-shareholder-analyst-call-prepared-remarks-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
SK hynix logo above a robotic arm placing memory chips on a wafer in a server data center.
Why SK hynix Could Be the Best AI Chip Stock to Buy Now
By Thomas Hughes | July 29, 2026
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$4.32 +0.03 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$4.32 0.00 (0.00%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$14.50 -0.03 (-0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$14.50 -0.01 (-0.03%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Evolus stock logo

Evolus NASDAQ:EOLS

$8.18 +0.41 (+5.28%)
Closing price 04:00 PM Eastern
Extended Trading
$8.16 -0.02 (-0.18%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$1.07 -0.03 (-2.73%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 +0.00 (+0.47%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas